This Practice Note explores the changes introduced to the regulation of medicinal products in the EU by the Falsified Medicines Directive to combat the increase in the incidence of falsified medicinal products. First, the Practice Note considers what is meant by the term ‘falsified medicinal product’, before looking at the measures introduced by the Falsified Medicines Directive: greater control of active substances, obligations for actors in the supply chain, the introduction of safety features on the packaging of medicinal products and the common logo for websites selling medicinal products. This Practice Note also provides an overview of the UK regime for falsified medicines.